Search

Your search keyword '"Buque, Xabier"' showing total 90 results

Search Constraints

Start Over You searched for: Author "Buque, Xabier" Remove constraint Author: "Buque, Xabier" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
90 results on '"Buque, Xabier"'

Search Results

1. Hepatic levels of S-adenosylmethionine regulate the adaptive response to fasting

2. FRI-472-YI Mitochondrial metabolism is disrupted by ciprofloxacin preventing cholangiocarcinoma cell proliferation

3. THU-210 Dysfunctional activation of the DNA damage response is associated with MASLD progression through an E2F2-dependent mechanism

4. FRI-343-YI APAP induced liver damage is prevented by activation of PPARgamma and PPAR-alpha

5. OS-101-YI Remodelling of hepatocyte cholesterol metabolism mediates colorectal liver metastasis

6. OS-042-YI Metabolic reprogramming induced by pravastatin prevents polycystic liver disease progression improving mitochondrial bioenergetics in cystic cholangiocytes

7. FRI-153 High prevalence of steatotic liver disease and systemic inflammation in hereditary fructose intolerance (HFI) patients independent of age, BMI and the presence of metabolic syndrome

8. TOP-229-YI The E2F2 target glycerophosphodiester phosphodiesterase domain containing 3 is involved in MASLD progression to HCC and related dyslipidemias

9. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

10. Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly

12. The E2F2-miR34a-5p axis is involved in the biliary metabolism dysregulation in NASH

13. Targeting the E2F/MCM axis in cholangiocarcinoma halts disease progression in experimental models by rewiring lipid metabolism

14. E2F2 deficiency protects from acetaminophen-induced hepatotoxicity while E2F1 is required to prevent the devastating effects

15. E2F2-promoted DNA damage in NASH worsens the metabolic scenario

16. Hypothalamic AMPK-ER Stress-JNK1 Axis Mediates the Central Actions of Thyroid Hormones on Energy Balance

17. S-Adenosylmethionine increases circulating very-low density lipoprotein clearance in non-alcoholic fatty liver disease

19. Correction: Corrigendum: Hepatic p63 regulates steatosis via IKKβ/ER stress

20. The uptake of extracellular lipids promotes cholangiocarcinoma progression

21. miR34a-5p is a target of E2F2 transcription factor in MAFLD-related HCC

22. Methionine adenosyltransferase 1a antisense oligonucleotides induce the fibroblast growth factor 21-driven recovery from obesity and associated hepatoesteatosis

23. The DNA damage response is involved in the metabolic dysregulation of MAFLD patients via inefficient fatty acid oxidation

24. Global multi-stakeholder endorsement of the MAFLD definition

25. Global multi-stakeholder endorsement of the MAFLD definition

26. Inhibition of ATG3 ameliorates liver steatosis by increasing SIRT1 in an autophagic-independent action

27. Liver GPR55 regulates NAFLD progression from steatosis to fibrosis

28. E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment

29. WED-408 - E2F2-promoted DNA damage in NASH worsens the metabolic scenario

30. WED-404 - The E2F2-miR34a-5p axis is involved in the biliary metabolism dysregulation in NASH

31. SAT-215 - Targeting the E2F/MCM axis in cholangiocarcinoma halts disease progression in experimental models by rewiring lipid metabolism

32. FRI-395 - E2F2 deficiency protects from acetaminophen-induced hepatotoxicity while E2F1 is required to prevent the devastating effects

33. The L‐α‐Lysophosphatidylinositol/G Protein–Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis

34. Solute Carrier Family 2 Member 1 Is Involved in the Development of Nonalcoholic Fatty Liver Disease

35. Liver osteopontin is required to prevent the progression of age‐related nonalcoholic fatty liver disease

36. FRI-343-NEDDylation inhibition as a new potential therapy of non-alcoholic fatty liver disease

37. PS-015-Role of methylation-controlled J-protein, endogenous repressor of the mitochondrial respiratory chain, in cholestatic liver disease

38. FRI-094-Targeting NEDDylation protects liver from acute drug-induced damage

39. Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD)

41. The L‐α‐Lysophosphatidylinositol/G Protein–Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis.

42. Pharmacological stimulation of p53 with low-dose doxorubicin ameliorates diet-induced nonalcoholic steatosis and steatohepatitis

43. Activation of p53 with low doses doxorubicin reduce the acumulation of lipids in two in vitro models of liver steatosis

44. is involved in the development of nonalcoholic fatty liver disease

45. Hypothalamic AMPK-ER Stress-JNK1 Axis Mediates the Central Actions of Thyroid Hormones on Energy Balance

46. Hepatic p63 regulates steatosis via IKKβ/ER stress

47. PS-008-E2F2 mediated repression of fatty acid B-oxidation is mitigated through CREB1 in progressive non-alcoholic fatty liver disease

48. Proteomic and lipidomic analysis of primary mouse hepatocytes exposed tometal and metal oxide nanoparticles

50. Solute carrier family 2 member 1is involved in the development of nonalcoholic fatty liver disease

Catalog

Books, media, physical & digital resources